| 查看: 319 | 回复: 2 | |||
[交流]
【求助】有没有虫子帮我查一下fasidotril这个药在国外有没有上市? 已有2人参与
|
|
因为我们单位没啥数据库,所以查不到。 fasidotril 法西多曲 ACE/NEP双向抑制剂 临床试验做到3期,但后来就没下文了,哪位好心的虫子帮个忙呢?帮我把它有没有上市,在哪上市的查一下? |
» 猜你喜欢
安捷伦液相色谱柱与方法开发指南
已经有4人回复
2026申请考核博士自荐-蛋白质组学/AI/药物设计/AIDD/化学生物学
已经有1人回复
药物学论文润色/翻译怎么收费?
已经有54人回复
中国医药行业发展现状:标准品推动药品检测水平提升
已经有1人回复
标准品的纯度对于药品质量的影响有多大?
已经有0人回复
如何制备符合技术要求的药品标准品?
已经有0人回复
对照品在药品研发中的不可或缺性
已经有0人回复
标准品的分类和用途,你知道多少?
已经有0人回复
杂质对照品价格如何界定和正确使用方法
已经有0人回复
nkbeholder
版主
![]()
![]()
![]()
![]()
- DRDEPI: 1
- 应助: 11 (小学生)
- 金币: 2945.1
- 散金: 4
- 红花: 5
- 帖子: 748
- 在线: 303.7小时
- 虫号: 202353
- 注册: 2006-03-01
- 性别: GG
- 专业: 药物化学
★ ★
madai26(金币+2):谢谢参与
warlen(金币+1):谢谢参与 2010-08-04 15:15:09
madai26(金币+2):谢谢参与
warlen(金币+1):谢谢参与 2010-08-04 15:15:09
|
这上面写到2期就中止了。 Originator Company: Bioprojet (France) Parent Company: Bioprojet Licensee: Eli Lilly Highest Phase: Discontinued II Development Status: Discontinued II, France, Congestive heart failure Discontinued II, France, Hypertension Discontinued Preclinical, France, Postmyocardial infarction Introduction: Fasidotril, the prodrug of its active metabolite fasidoprilat, is a mixed inhibitor of ACE and neutral endopeptidase. It was undergoing phase II development with Bioprojet in France for the treatment of congestive heart failure and hypertension. It was also in preclinical development for postmyocardial infarction. However, development appears to have been discontinued. In October 2001, Bioprojet and Eli Lilly announced a development and commercialisation collaboration. Under the terms of the agreement, Lilly received exclusive worldwide commercialisation rights excluding Japan and certain countries in Europe. Lilly was to continue to develop fasidotril through to registration, and was to manufacture the finished product; Bioprojet was to manufacture the bulk material. |
2楼2010-08-04 14:45:13
mrzouhao
超级版主
![]()
![]()
![]()
![]()
- DRDEPI: 1
- 应助: 179 (高中生)
- 贵宾: 0.108
- 金币: 100882
- 散金: 11601
- 红花: 134
- 沙发: 22
- 帖子: 46786
- 在线: 4409.4小时
- 虫号: 201350
- 注册: 2006-02-28
- 专业: 药剂学
3楼2010-08-04 15:13:10














回复此楼